Multiple Myeloma Program
Multiple myeloma is a type of cancer that begins in plasma cells (white blood cells that produce antibodies). Also called Kahler disease, myelomatosis, and plasma cell myeloma.
Sarcoma and Soft Tissue Oncology Program
Rutgers Cancer Institute Sarcoma and Soft Tissue Oncology program provides comprehensive multidisciplinary care to patients with soft tissue sarcomas, osteosarcoma, Ewing sarcoma, Kaposi sarcoma, uterine sarcomas, gastrointestinal stromal tumors (GIST) and others.
Ganesan Army Breakthrough Award Feb 2021
$1.33 Million Award Supports Research to Better Inform HER2 Breast Cancer Treatment
A Rutgers Cancer Institute collaboration with George Mason University received the U.S. Army’s Breast Cancer Research Program Breakthrough Award to quickly confirm if an identified HER2 biomarker can indicate success likelihood of personalized treatments. Read more
Cancer Metabolism
.coe{
font: normal 24px Trebuchet MS,sans-serif;
color: #cc0033;
padding: 6px 0;
}
Breaking Through the Latest Breakthroughs.
Immuno-oncology has taken center stage in innovation in cancer treatment in recent years. Immunotherapy is the latest breakthrough, becoming an effective tool in prolonging the lives of patients with many different kinds of cancer. But while immunotherapy is effective in some cancers, it is not a universal tool, nor is it without its drawbacks, including severe and unpredictable toxicities.
Good Manufacturing Practices (GMP)
.coe{
font: normal 24px Trebuchet MS,sans-serif;
color: #cc0033;
padding: 6px 0;
}
In-House Technology.
Housed within Rutgers Cancer Institute is a Good Manufacturing Practices (GMP) facility. Our GMP facility enables the production of vectors and cells for adoptive cell transfer in support of clinical trials.